MicroRNA-186 suppresses lung cancer progression by targeting SIRT6

Abstract

MicroRNAs are a class of small non-coding RNA molecules that play crucial roles in the initiation and progression of lung cancer. This study was undertaken to investigate the expression and roles of miR-186 in lung cancer. Ectopic expression experiments demonstrated that miR-186 functions as a tumor suppressor. Bioinformatic predictions, a luciferase reporter assay, and protein expression analysis suggested that miR-186 could inhibit the protein levels of SIRT6, a purported tumor suppressor gene. Collectively, our results indicated that miR-186 could inhibit lung cancer progression through targeting SIRT6 and that miR-186 may be a therapeutic target for lung cancer.

Keywords

Lung cancer microRNA miR-186 SIRT6 apoptosis

1. Introduction

In China and many developed countries, lung cancer has become the most frequent cause of cancer-related death. Non-small cell lung carcinoma (NSCLC) accounts for 70–80% of all lung cancers and is generally diagnosed at an advanced stage [1]. Despite advances made in clinical treatment, the prognosis of NSCLC patients, especially those with advanced disease, is still very poor. The initiation and progression of NSCLC are part of a multistep process, which is attributed to the activation of oncogenes and inactivation of tumor suppressor genes [2]. Currently, the molecular mechanism underlying the development of NSCLC remains poorly understood.

MicroRNAs (miRNAs/miRs) are a class of short (22–24 nucleotides in length), single-stranded RNA molecules. MicroRNAs silence protein expression by either inhibiting translation elongation or inducing mRNA decay [3]. The expression and role of cancer-related miRNAs have been extensively explored in lung cancer [4]. A number of miRNAs were found to be deregulated in lung cancer; furthermore, their expression levels were associated with poor outcome [5]. Notably, upregulation of let-7 inhibits lung cancer cell cycle arrest by suppressing expression of RAS [6] or HMGA2 [7]. Generally, multiple miRNAs can repress one gene or one miRNA may repress multiple target genes, resulting in complex regulatory feedback networks. In different pathological and cellular environments, miRNAs have been reported to be involved in multiple cellular processes, such as differentiation, morphogenesis, and angiogenesis [8, 9, 10]. Many reports have indicated a role for miRNAs in the etiology and pathogenesis of cancer; microRNAs may fully or partially base pair with the 3’-UTR of oncogenes or tumor suppressors [11, 12]. Although the global alteration of miRNA expression is a hallmark of tumorigenesis, the studies addressing the role of miRNAs in cellular transformation and tumorigenesis remain unclear [13, 14]. Previous studies have shown that miR-186 acted as a tumor suppressor in different cancers [15, 16, 17]. Accordingly, miR-186 could inhibit proliferation, cell cycle progression, migration, and invasion of NSCLC cells by targeting different genes. In clinical samples, the downregulation of miR-186 correlated with poorer survival of NSCLC patients. Thus, identification of the miRNA targets would be critical to understanding the miRNA pathway and underlying molecular signaling associated with NSCLC progression and development.

Here, we identify the expression of miR-186 in specimens from patients with NSCLC. Furthermore, we investigated the function of miR-186 in NSCLC cells. Our findings suggest that SIRT6 translation is directly inhibited by miR-186, and miR-186 potentially acts as a growth suppressor in A549 cells.

2. Materials and methods

2.1 Tissue samples

A total of 4 patients, who were diagnosed with primary NSCLC in the Department of Cardiothoracic Surgery at the First People’s Hospital of Yunnan Province from 2012 to 2016, were included in this study. None of these patients received chemotherapy or radiotherapy before surgery. Tumor and matched non-tumor lung tissue samples were collected, rapidly frozen in liquid nitrogen, and stored at $-$ 80 ${}^{\circ}$ C. Ethical approval from the hospital and fully informed patient consent were obtained before sample collection.

2.2 Cell culture, RNA oligonucleotides, and transfection

The NSCLC cell line (A549) was cultured in RPMI1640 (GIBCO-BRL) medium supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 U/ml) at 37 ${}^{\circ}$ C in a humidified atmosphere of 95% air and 5% CO ${}_{2}$ . MiR-186 mimic and inhibitor were designed and synthesized by the Guangzhou RiBio company (Guangzhou, China). The cells were plated in antibiotic-free growth medium at 30–40% confluence, approximately 24 h before transfection. The RNA oligonucleotides were transfected at a final concentration of 50 nM by using Lipofectamine 2000 (Invitrogen, USA), according to the manufacturer’s protocol. Further treatment occurred 72 h after transfection.

2.3 Cell viability assay

Cell proliferation was determined by using the CellTiter96 (Promega, Madison, WI) and Cell Counting Kit-8 assay kit (Dojindo, Kumamoto, Japan) assays according to the manufacturer’s instructions.

2.4 Flow cytometric analysis of the cell cycle

The A549 cells (4 $\times$ 10 ${}^{5}$ cells) were collected and fixed. After incubation in RNase A (1 $\mu$ g/ml) for 30 min at 37 ${{}^{\circ}}$ C, the cells were stained with propidium iodide (50 $\mu$ g/ml). Flow cytometric analysis was performed using a FACScan instrument (Becton Dickinson, Mountain View, CA, USA) and CellQuest software (Becton Dickinson, San Jose, CA, USA), as previously reported.

2.5 Flow cytometric analysis of apoptosis

An annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Oncogene Research Products, Boston, MA, USA) was used to detect apoptosis, as previously described. All of the samples were assayed in triplicate.

2.6 RNA extraction and qRT-PCR

Total RNA, including miRNA, was extracted from cell lines and tissue samples using TRIzol reagent (Invitrogen, USA). The RNA was synthesized into cDNA using M-MLV reverse transcriptase (Promega, USA) in a 25 $\mu$ l volume. Real-time PCR was conducted using SYBR Green mix (TaKaRa, China) in a 20 $\mu$ l reaction volume on a MJ Opticon Monitor Chromo 4 instrument (Bio-Rad, USA) using the following protocol: 95 ${}^{\circ}$ C for 5 min; 35 cycles of 95 ${}^{\circ}$ C for 10 s, 60 ${}^{\circ}$ C for 20 s, and 70 ${}^{\circ}$ C for 10 s. The expression of each miRNA was normalized to small nuclear RNA and calculated using the 2 ${}^{-\Delta\Delta\text{Ct}}$ method.

2.7 Luciferase reporter assay

To create a luciferase reporter plasmid, the 3’-UTR fragment containing putative binding sites for miR-186 was PCR-amplified from the genomic DNA of A549 cells. The PCR products were gel-purified, digested, and inserted into the digested psiCheck-2 plasmid (Promega, USA) between the Xho I and Not I sites. SIRT6 3’-UTR-targeted site mutations were generated using the KOD-plus mutagenesis kit (Toyobo, Japan), according to the manufacturer’s protocol.

A549 cells cultured in a 96-well plate were co-transfected with 200 ng/ $\mu$ l of plasmid and 50 nM of ei- ther a miRNA mimic or a non-specific control miRNA (NC). Approximately 48 hours after co-transfection, luciferase activity was detected by the Dual-Glo luciferase assay kit (Promega, USA). Transfections were performed in duplicate and repeated 3 times.

2.8 In vivo studies

Animal studies were performed according to the institutional guidelines. The miR-NC-, miR-186-, SIRT6-, and SIRT6+miR-186-transfected A549 cells (5 $\times$ 10 ${}^{6}$ ) were suspended in 100 $\mu$ l of phosphate-buffered saline, and then injected subcutaneously into either side of the posterior flank of the same male BALB/c athymic nude mouse at 5–6 weeks of age. Tumor growth was examined weekly for at least 5 weeks. Tumor size was monitored by measuring the tumor length (L) and width (W) with calipers, and the tumor volumes were calculated using the formula: (L $\times$ W ${}^{2}$ ) $\times$ 0.5.

2.9 Statistical analysis

The SPSS 10.0 program was used for general statistical and survival analysis. Experimental data were expressed as the mean $\pm$ SEM. The differences between groups were analyzed using Student’s t-test. All tests performed were two-sided. Differences were considered statistically significant at $P<$ 0.05.

3. Results

3.1 Identification of aberrant miRNA expression in NSCLC tissue samples

The expression level of miR-186 was determined by quantitative real-time PCR of NSCLC tissue from 8 patients who underwent surgical resection in our department. The clinical characteristics of these patients are listed in Table 1. Our results confirmed that miR-186 was downregulated in all 8 lung cancer tissues compared with that in adjacent normal tissues (Fig. 1).

Table 1
The clinical characteristics of patients in this study

Patient	Age	Pathological type	Pathological
number	(years)		grading
No.1	47	Squamous carcinoma	I
No.2	55	Squamous carcinoma	III
No.3	48	Adenocarcinoma	II–III
No.4	56	Squamous carcinoma	III
No.5	47	Adenocarcinoma	III
No.6	52	Squamous carcinoma	II
No.7	54	Squamous cell carcinoma	III
No.8	61	Squamous cell carcinoma	II

Figure 1.

miR-186 expression was analyzed by real-time PCR and standardized against the expression of small nuclear RNA U6 (snU6), which was used as an endogenous control. The data are shown as Log10 of relative quantification (2 ${}^{-\Delta\Delta\text{Ct}}$ ).

3.2 miR-186 suppresses proliferation of NSCLC cells

To test if miR-186 functions as a tumor suppressor, in vitro experiments were performed to determine the effect of miR-186 upregulation on NSCLC cell proliferation. The CCK-8 assays were performed to detect cell viability. A549 cells transfected with the miR-186 mimic grew more slowly than cells transfected with the control (NC) (Fig. 2A). The inhibitory rate of miR-186 mimic-transfected cells was higher than that of NC-transfected cells (Fig. 2B).

Figure 2.

miR-186 inhibits cell growth and induces senescence in A549 and 95D cells. (A) A549 was transfected with 50 nM of either the miRNA mimic (open circles) or the negative control (NC, filled circles) in 96-well plates on day 0. Cell viability assays were performed on the days indicated. (B) The effect of miR-186 in A549 cells was examined by using a CCK-8 assay. Data represent the average of triplicate values. Error bars, SEM. $*$ $p\leqslant$ 0.05, ${}^{***}$ $p\leqslant$ 0.001 compared with the non-specific control.

3.3 miR-186 induces cell cycle arrest in NSCLC cells

To further ascertain the mechanism by which miR-186 expression mediated cell proliferation, the cell cycle of A549 cells was detected using flow cytometric analysis after transfection of either the miR-186 mimic or NC. As seen in Fig. 3, miR-186 overexpression caused significant G ${}_{0}$ /G ${}_{1}$ arrest in A549 cells. This result showed that miR-186 expression induced cell cycle arrest in the NSCLC cells.

Figure 3.

Cell cycle profile changes were assessed by flow cytometry using propidium iodide (PI) staining to measure the DNA content.

3.4 miR-186 triggers apoptosis in NSCLC cells

To investigate if the introduction of miR-186 contributed to apoptosis, flow cytometric analysis was performed after transfection of A549 cells with either the miR-186 mimic or miR-NC. A549 cells underwent apoptosis 48 h after transfection with the miR-186 mimic. In miR-186 mimic-transfected A549 cells, the rates of early (UR quadrant) and late apoptosis/ necrosis (UR quadrant) were 28.80% and 53.69%, respectively. In contrast, the rates of early and late apoptosis/necrosis in miR-NC-transfected A549 cells were 3.88% and 0.8%, respectively (Fig. 4). These results suggest that ectopic expression of miR-186 could induce enhanced apoptosis in A549 cells.

Figure 4.

Ectopic miR-186 expression enhances apoptosis of A549 cells. Approximately 48 h after transfection with either pre-miR-186 or miR-NC, A549 cells were collected for apoptosis analysis. The apoptotic rates of the cells were detected by flow cytometry.

3.5 miR-186 directly targets the SIRT6 gene by interacting with the 3’-UTR

Using in silico miRNA target identification software, including TargetScan, miRBase, and PicTarget, SIRT6 was identified as a putative target of miR-186 (Fig. 5A). Consequently, we subcloned WT-3’-UTR or its mutant, MUT-3’-UTR, which lacks the miR-186 binding sequences, downstream of the firefly luciferase reporter gene in the pLUC vector. Then, each construct was co-transfected with either the miR-186 mimic, miR-NC, or miR-186 inhibitor into A549 cells. The relative luciferase activity of the reporter construct containing the wild-type 3’-UTR decreased by 70% when the miR-186 mimic was co-transfected. However, the relative luciferase activity of the reporter construct increased by 27.4% when the miR-186 inhibitor was co-transfected. The inhibitory effect of the miR-186 mimic was abolished in the mutated construct (Fig. 5B).

Figure 5.

SIRT6 is a direct target of miR-186. (A) Sequence alignment between miR-186 and the 3’-UTR of human SIRT6 mRNA, seed-matching or seed-mutated regions. (B) Relative luciferase activity was calculated according to (Rluc ${}_{\text{miRNA}}$ /Luc ${}_{\text{miRNA}}$ )/(Rluc ${}_{\text{no\_target}}$ /Luc ${}_{\text{no\_target}}$ ). (C) SIRT6 mRNA levels were analyzed by real-time PCR and standardized against those of the endogenous control, $\beta$ -actin. Relative expression levels were determined for the non-specific control (NC). (D) SIRT6 protein levels were examined by Western blotting, using GADPH as a loading control. Error bars: SEM. ${}^{*}$ $p\leqslant$ 0.05, ${}^{**}$ $p\leqslant$ 0.01, compared with NC.

Figure 6.

SIRT6 induces cell proliferation and inhibits cell apoptosis. (A) Effect of miR-186, SIRT6, or SIRT6+miR-186 on the growth of A549 cells, as determined by the CCK-8 assay. (B) The inhibitory rate of miR-186, SIRT6, or SIRT6+miR-186 on the growth of A549 cells, as determined by CCK-8 assay. (C) Summary of cell cycle profile changes. Effect of transient transfection of miR-186, SIRT6, or SIRT6+miR-186 on the cell cycle of A549, as determined by flow cytometry. ${}^{*}$ $p\leqslant$ 0.05, ${}^{**}$ $p\leqslant$ 0.01, ${}^{***}$ $p\leqslant$ 0.001. (D) Apoptosis of the cells was measured by flow cytometry.

Figure 7.

miR-186 suppresses tumor growth in vivo. (A) Tumor formation in nude mice. The group contained ten mice ( $n=$ 10); data represent means $\pm$ SEM; ${}^{*}$ $p<$ 0.05, compared with the NC group. A representative photograph is shown. (B) Tumor weight in nude mice. The group contained ten mice ( $n=$ 10); data represent means $\pm$ SEM; ${}^{*}$ $p<$ 0.05, compared with the NC group. Representative photograph is shown. NC- and miR-186-transfected cells were injected into the left and the right flank of the same nude mouse, respectively.

Next, we determined whether miR-186 expression affects endogenous SIRT6 expression at both the transcriptional and translational levels. As shown in Fig. 5C, the level of SIRT6 mRNA in miR-186 mimic-transfected A549 cells was significantly inhibited by 61% compared with that in miR-NC-transfected cells. Western blot analysis showed that the level of SIRT6 protein expression was also inhibited by treatment with the miR-186 mimic in A549 cells (Fig. 5D). Thus, these data suggest that miR-186 reduces SIRT6 expression by inhibiting translation and/or causing mRNA instability.

3.6 Inhibition of SIRT6 is potentially involved in the tumor suppressor function of miR-186

To investigate whether downregulation of SIRT6 was involved in miR-186-induced growth suppression and apoptosis enhancement, we examined whether SIRT6 reversed the inhibition of cell growth caused by miR-186. A549 cells were co-transfected with miR-186 mimic and pEZ-M02-SIRT6, which contained the entire SIRT6 coding sequence but lacked the 3’UTR of SIRT6 mRNA. The resulting SIRT6 overexpression rescued the suppression of cell viability caused by miR-186 (Fig. 6A and B). At the same time, SIRT6 significantly inhibited cell cycle arrest and apoptosis in A549 cells (Fig. 6C and D). Moreover, co-transfection of SIRT6 and miR-186 partially rescued miR-186-induced growth promotion and apoptosis inhibition in A549 cells. These results suggest that targeting SIRT6 may be a mechanism of miR-186-mediated tumor suppression in lung cancer cells.

At 28 days, the average volume of the tumors formed from miR-186- and miR-186+SIRT6- transfected A549 cells was significantly lower than that of tumors formed from miR-NC- and SIRT6-transfected cells. Notably, the tumor suppressor effect of SIRT6 knockdown mediated by miR-186 was similar to that of ectopic miR-186 expression.

3.7 Effect of miR-186 expression on in vivo proliferation of NSCLC cells

To explore whether the level of miR-186 expression affects tumorigenesis, A549 cells transfected with either the miR-186 mimic, miR-NC, SIRT6, or SIRT6+miR-186 were inoculated into male nude mice. During the whole-tumor growth period, tumors from the miR-186 mimic-transfected A549 cells grew slower, but the SIRT6-transfected cells grew faster in compassion with the negative control (Fig. 7A). Five weeks after inoculation, the average weight of the tumors from miR-186 mimic-transfected A549 cells was less than that of the control mice. The tumors from SIRT6-transfected cells, however, were larger than those of the control mice (Fig. 7B). These results suggest that the level of miR-186 expression was significantly associated with the in vivo proliferation capacity of NSCLC cells.

4. Discussion

In addition to protein-encoding genes, there is sufficient evidence that miRNAs have more than a cursory role in the initiation and development of human cancers by functioning as agents of the RNA interference pathway. The present study elucidated the biological roles of only a small fraction of identified miRNAs. These miRNAs participate in cancer-related biological processes, such as cell cycle arrest, proliferation, apoptosis, and chemoresistance [18, 19]. Until recently, the effects of miRNAs in NSCLC and the molecular mechanism by which miRNAs modulate the behavior of NSCLC cells remained unclear.

In the present study, we showed that miR-186 is significantly downregulated in NSCLC. Although very few studies explored the role of miR-186 in human cancers, miR-186 was one of the 8 best-studied miRNAs upregulated in pancreatic cancer [20]. Previous studies have shown that miR-186 acted as a tumor suppressor in different cancers [21]. By targeting different genes, miR-186 could inhibit proliferation, cell cycle progression, migration, and invasion of NSCLC. Myatt et al. showed that overexpression of miR-186 contributed to endometrial tumorigenesis, which suggests that miR-186 may play an oncogenic role in other cancer types [22]. On the other hand, Lv et al. reported that deletion of miR-186 occurred in 15% ( $n=$ 48) of primary medulloblastomas, which suggests a potential tumor-suppressive function [23]. In the present study, we provide clinical evidence that the expression of miR-186 is markedly downregulated in NSCLC, and ectopic miR-186 expression suppresses the proliferation of NSCLC cells both in vitro and in vivo. These results suggest that miR-186 acted as a tumor suppressor in NSCLC cancer. Perhaps, miR-186 plays a dual role as either an oncogenic or anti-tumor miRNA; the specific role of miR-186 may vary by cancer type. Although these findings show that miR-186 may have a vital role in tumor progression, its role in human NSCLC remains unclear.

Our study is the first to show that miR-186 functions as an inhibitor of tumor growth in NSCLC cells. Moreover, this is the first report of direct interaction between the oncogene, SIRT6, and miR-186; miR-186 targets SIRT6 via binding to the 3’-UTR of SIRT6 mRNA in NSCLC cells in vitro and in vivo. SIRT6 is a highly specific NAD ${}^{+}$ -dependent histone deacetylase and ADP-ribosyl transferase. Furthermore, SIRT6 has been implicated in DNA repair, genomic stability, and glucose and fatty acid metabolism [24, 25, 26]. Thus, several reports have proposed that SIRT6 is a potential tumor suppressor gene in different cancer types [27, 28]. These results were consistent with the observed reduction of SIRT6 in cell lines and tissues of hepatocellular carcinomas and colon adenocarcinomas [29]. Moreover, SIRT6 has been reported to be overexpressed in the B cells of patients with chronic lymphocytic leukemia (CLL) and in pancreatic cancer cell lines [30]. This indicates that SIRT6 may behave as either an oncogene or a tumor suppressor gene in different cancer types, depending on the tissue type and cellular environment [31]. Here, we have reported miR-186 overexpression in NSCLC tissues and cell lines. By inducing cell cycle arrest and apoptosis, miR-186 acts as a tumor suppressor by directly regulating the oncogene, SIRT6. Our experimental data may provide a strategy for targeting the miR-186/SIRT6 interaction as a novel therapeutic application to treat lung cancer patients.

Footnotes

Acknowledgments

This study was supported by the Applied Basic Research Project of Joint Special Fund of Kunming Medical University from Yunnan Province (No. 2017FE467 (-117) and 2017FE468(-109) and Scientific Research Fund from Yunnan Provincial Department of Education (2016ZDX009).

References

Jemal

et al., Cancer statistics, 2008, CA-a Cancer Journal for Clinicians 58 (2008), 71–96.

Byers

L.A.

et al., Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1, Cancer Discovery 2 (2012), 798–811.

Zhang

et al., Exosome and exosomal microRNA: Trafficking, sorting, and function, Genomics Proteomics Bioinformatics 13 (2015), 17–24.

Friedman

R.C.

et al., Most mammalian mRNAs are conserved targets of microRNAs, Genome Research 19 (2009), 92–105.

Hua

et al., MiRConnect 2.0: Identification of oncogenic, antagonistic miRNA families in three human cancers, BMC Genomics 14 (2013), 179.

Croce

C.M.

, Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics 10 (2009), 704–714.

Johnson

S.M.

et al., RAS is regulated by the let-7 microRNA family, Cell 120 (2005), 635–647.

Mitra

et al., Concordant dysregulation of miR-5p and miR-3p arms of the same precursor microRNA may be a mechanism in inducing cell proliferation and tumorigenesis: A lung cancer study, RNA 21 (2015), 1055–1065.

Zhang

et al., MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/beta-catenin pathway in non-small cell lung cancer, Life Sciences, 2017.

10.

Edmonds

M.D.

et al., MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer, Journal of Clinical Investigation 126 (2016), 349–364.

11.

Zhang

et al., Altered RNA editing in 3’ UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors, Scientific Reports 6 (2016), 23226.

12.

Huang

et al., MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer, International Journal of Oncology 49 (2016), 1437–1444.

13.

Y.R.

and Yang

W.X.

, SOX-mediated molecular crosstalk during the progression of tumorigenesis, Seminars in Cell & Developmental Biology 63 (2017), 23–34.

14.

et al., The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis, Oncogene 36 (2017), 989–998.

15.

Cai

et al., MiR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation, Cancer Research 73 (2013), 756–766.

16.

Cui

et al., MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells, Tumor Biology 35 (2014), 8933–8937.

17.

Huang

et al., MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer, International Journal of Oncology 49 (2016), 1437–1444.

18.

Song

et al., MiR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM, Cancer Research 74 (2014), 3031–3042.

19.

Xie

et al., MiR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis, World Journal of Gastroenterology 20 (2014), 17439–17447.

20.

Zhang

et al., Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis, World Journal of Surgery 33 (2009), 698–709.

21.

Wang

et al., The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186, Journal of Biological Chemistry 292 (2017), 15395–15407.

22.

Myatt

S.S.

et al., Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer, Cancer Research 70 (2010), 367–377.

23.

S.Q.

et al., Genetic alterations in microRNAs in medulloblastomas, Brain Pathology 22 (2012), 230–239.

24.

Vazirani

R.P.

et al., Disruption of adipose Rab10-Dependent insulin signaling causes hepatic insulin resistance, Diabetes 65 (2016), 1577–1589.

25.

Blanco

C.L.

et al., Peripheral insulin resistance and impaired insulin signaling contribute to abnormal glucose metabolism in preterm baboons, Endocrinology 156 (2015), 813–823.

26.

Jia

et al., Emerging roles of SIRT6 on telomere maintenance, DNA repair, metabolism and mammalian aging, Molecular and Cellular Biochemistry 364 (2012), 345–350.

27.

Vitiello

et al., Multiple pathways of SIRT6 at the crossroads in the control of longevity, cancer, and cardiovascular diseases, Ageing Research Reviews 35 (2017), 301–311.

28.

Zhou

et al., SIRT6 inhibits growth of gastric cancer by inhibiting JAK2/STAT3 pathway, Oncology Reports 38 (2017), 1059–1066.

29.

Min

et al., Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin, Nature Cell Biology 14 (2012), 1203–1211.

30.

Bauer

et al., The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses, Journal of Biological Chemistry 287 (2012), 40924–40937.

31.

N.L.

et al., NR1D1 recruitment to sites of DNA damage inhibits repair and is associated with chemosensitivity of breast cancer, Cancer Research 77 (2017), 2453–2463.

MicroRNA-186 suppresses lung cancer progression by targeting SIRT6

Abstract

Keywords

1. Introduction

2. Materials and methods

2.1 Tissue samples

2.2 Cell culture, RNA oligonucleotides, and transfection

2.3 Cell viability assay

2.4 Flow cytometric analysis of the cell cycle

2.5 Flow cytometric analysis of apoptosis

2.6 RNA extraction and qRT-PCR

2.7 Luciferase reporter assay

2.8 In vivo studies

2.9 Statistical analysis

3. Results

3.1 Identification of aberrant miRNA expression in NSCLC tissue samples

Table 1 The clinical characteristics of patients in this study

3.7 Effect of miR-186 expression on in vivo proliferation of NSCLC cells

4. Discussion

Footnotes

Acknowledgments

References

Table 1
The clinical characteristics of patients in this study